

Disclaimer :

The Competition DG makes the information provided by the notifying parties in section 1.2 of Form CO available to the public in order to increase transparency. This information has been prepared by the notifying parties under their sole responsibility, and its content in no way prejudices the view the Commission may take of the planned operation. Nor can the Commission be held responsible for any incorrect or misleading information contained therein.

M.8956 • BIOGEN / SAMSUNG BIOLOGICS / BIOEPSIS JV

SECTION 1.2

Description of the concentration

1. By exercise of a call option foreseen in the original Joint Venture between Biogen and Samsung Bioepis, Biogen will increase its shareholding in Bioepis, which, post-transaction, will be jointly controlled with Samsung BioLogics.
2. The primary business activities of the undertakings involved are:
 - Biogen is a biopharmaceutical company headquartered in Cambridge, Massachusetts, U.S. Biogen is active in discovering, developing and delivering worldwide therapies for serious neurological and neurodegenerative diseases.
 - Samsung BioLogics is headquartered in Incheon, South Korea. It is active in biopharmaceutical manufacturing and development.
 - Samsung Bioepis is based in Incheon, South Korea. It is active in the development of biosimilar medicines. Its pipeline consists of biosimilar candidates, focusing on immunology, oncology and metabolic diseases.